Phastar Secures SCOPE US ‘Best in Show’ Accolade for Clinical Intelligence Platform

Phastar Secures SCOPE US ‘Best in Show’ Accolade for Clinical Intelligence Platform

London, UK, and Durham (NC), US – February 13^th, 2025: Phastar, a global specialist biometrics & data science contract research organization (CRO), won a Best of Show Award at Summit for Clinical Ops Executives (SCOPE) US 2025.

Having taken place in Orlando, Florida from the 3^rd-6^th February, SCOPE’s 300+ attendees voted on more than 60 product finalists to declare Phastar’s Clinical Intelligence Platform as the winner. By leveraging data visualizations and analytics, Phastar’s award winning Clinical Intelligence Platform provides sponsors with near real-time access to information and offers user-friendly tools for deep data understanding and rapid anomaly resolution.

A new addition to the platform is an RBQM app. The tool supports critical RBQM processes like Risk Assessment, Central Monitoring, Issue Management, Risk Reassessment, Targeted Site Monitoring, and KRI Tracking, while ensuring regulatory compliance and enabling continuous, data-driven improvements throughout the clinical trial. A key feature is the ability to assign risk scores to different clinical sites or activities based on predefined criteria, enabling effective prioritization of site visits.

Also newly added, is the Recruitment Forecasting app, which uses advanced statistical modelling to predict participant progression and treatment administration timelines, accounting for late site openings and real-time data updates.

Graham Clark, CEO at Phastar, commented: “We are delighted to have been honored with the SCOPE Best in Show award, recognizing our Clinical Intelligence Platform for its ability to maximize the value of data for our clients. Our platform ensures that data is accessible, consumable, and actionable in real time, empowering users with intuitive insights. SCOPE provided a fantastic opportunity to showcase how we are leveraging new technologies alongside advanced statistical and data analysis expertise to accelerate drug development. It also served as an invaluable space to connect with other industry innovators who share our vision for the future of clinical research.”

For further information on Phastar’s solutions, please visit here.

-END-

About Phastar